Review of a new fully liquid, hexavalent vaccine: Hexaxim

Bibliography

• Pichichero ME. New combination vaccines. Pediatr Clin North Am 2000;47(2):407-26
   PubMed Web of Science ®Google Scholar
• Edwards KM, Decker MD. Combination vaccines: hopes and challenges. Pediatr Infect Dis J 1994;13(5):345-7
   PubMed Web of Science ®Google Scholar
• Mullany L. Considerations for implementing a new combination vaccine into managed care. Am J Manag Care 2003;9(1 Suppl):S23-9
   PubMed Web of Science ®Google Scholar
• Obaro SK, Palmer A. Vaccines for children: policies, politics and poverty. Vaccine 2003;21(13-14):1423-31
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/06/WC500129095.pdf [Accessed December 2012]
   Google Scholar
• Sanofi Pasteur. Available from: www.sanofipasteur.com [Accessed December 2012]
   Google Scholar
• WHO. WHO prequalified vaccines. Available from: http://www.who.int/immunization_standards/vaccine_quality/PQ_vaccine_list_en/en [Accessed December 2012]
   Google Scholar
• Plotkin SA, Liese J, Madhi SA, Ortiz E. A DTaP-IPV//PRP approximately T vaccine (Pentaxim): a review of 16 years' clinical experience. Expert Rev Vaccines 2011;10(7):981-1005
   PubMed Web of Science ®Google Scholar
• Huang Y, Bi J, Zhang Y, A highly efficient integrated chromatographic procedure for the purification of recombinant hepatitis B surface antigen from Hansenula polymorpha. Protein Expr Purif 2007;56(2):301-10
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Voelker R, Santos-Lima E, Zambrano B. Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10-45 years. Vaccine 2010;28(20):3595-601
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/12/WC500135727.pdf [Accessed December 2012]
   Google Scholar
• Agency EM. European Medicines Agency recommends suspension of Hexavac. European Medicines Agency recommends suspension of Hexavac 2013(January 2013)
   Google Scholar
• Tichmann I, Preidel H, Grunert D, Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine 2005;23(25):3272-9
   PubMed Web of Science ®Google Scholar
• Floreani A, Baldo V, Cristofoletti M, Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine 2004;22(5-6):607-10
   PubMed Web of Science ®Google Scholar
• Lu CY, Chiang BL, Chi WK, Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 2004;40(6):1415-20
   PubMed Web of Science ®Google Scholar
• WHO Publication. Hepatitis B vaccines: WHO position paper–recommendations. Vaccine 2010;28(3):589-90
   PubMedGoogle Scholar
• European Medicines Agency. Summary of opinion. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/06/WC500129095.pdf [Accessed December 2012]
   Google Scholar
• Ceyhan M, Santos-Lima E. Immunogenicity and Safety of an Investigational Hexavalent Fully Liquid DTaP-IPV-Hep B-PRP-T Vaccine (Hexaxim™) Given at 2, 3, 4 Months of Age and as a Booster at 15-18 Months Compared to Licensed Vaccines in Turkish Infants. 5th Asian Congress of Pediatric Infectious Diseases; 23-26 September 2010; Taipei, Taiwan
   Google Scholar
• Lopez P, Mohs AA, Consuelo-Miranda M, Immunogenicity and safety of a primary series of a new fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine (Hexaxim) co-administered with Prevenar and Rotarix in healthy children in Latin America. 15th International Congress on Infectious Diseases (ICID); 13-16 June;2012; Bangkok, Thailand
   Google Scholar
• Tregnaghi MW, Zambrano B, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. Pediatr Infect Dis J 2011;30(6):e88-96
   PubMed Web of Science ®Google Scholar
• Madhi SA, Mitha I, Cutland C, Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatr Infect Dis J 2011;30(4):e68-74
   PubMed Web of Science ®Google Scholar
• Aquino AG, Brito MG, Doniz CE, A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children. Vaccine 2012;30(45):6492-500
   PubMed Web of Science ®Google Scholar
• Macias M, Lanata CF, Zambrano B, Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatr Infect Dis J 2012;31(8):e126-32
   PubMed Web of Science ®Google Scholar
• Lanata C, Zambrano B, Ecker L, Immunogenicity and safety of a Fu& vlly liquid DTaP-IPV-Hep B-PRP-T vaccine at 2-4-6 months of age in peru. J Vaccines Accination 2012;3(1):e88-96
   Google Scholar
• Kosalaraksa P, Thisyakorn U, Benjaponpitak S, Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants. Int J Infect Dis 2011;15(4):e249-56
   PubMed Web of Science ®Google Scholar
• Madhi SA, Mitha I, Koen A, Post-primary antibody persistence and immunogenicity/safety of an investigational DTaP-IPV-Hep B-PRP-T (Hexaxim™) booster vaccine compared to licensed vaccines in South Africa. 7th Congress of the World Society for Pediatric Infectious Diseases (WSPID); 16-19 November 2011; Melbourne, Australia
   Google Scholar
• Tregnaghi M, Zambrano B, Santos-Lima E. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants. Pediatr Infect Dis J 2012;31(1):e24-30
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO position paper on Haemophilus influenzae type b conjugate vaccines. Replaces WHO position paper on Hib vaccines previously published in the Weekly Epidemiological Record. Wkly Epidemiol Rec 2006;81(47):445-52
   PubMedGoogle Scholar
• Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010;17(7):1055-65
   PubMed Web of Science ®Google Scholar
• Eskola J, Ward J, Dagan R, Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 1999;354(9195):2063-8
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Deloria MA, Rennels MB, A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics 1997;100(5):772-88
   PubMed Web of Science ®Google Scholar
• Dagan R, Poolman JT, Zepp F. Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates. Expert Rev Vaccines 2008;7(1):97-115
   PubMed Web of Science ®Google Scholar
• Carlsson RM, Trollfors B. Control of pertussis–lessons learnt from a 10-year surveillance programme in Sweden. Vaccine 2009;27(42):5709-18
   PubMedGoogle Scholar
• Bonmarin I, Levy-Bruhl D, Baron S, Pertussis surveillance in French hospitals: results from a 10 year period. Euro Surveill 2007;12:1
   PubMedGoogle Scholar
• Rendi-Wagner P, Paulke-Korinek M, Stanek G, Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria. Pediatr Infect Dis J 2007;26(9):806-10
   PubMed Web of Science ®Google Scholar
• Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 2006;118(3):978-84
   PubMed Web of Science ®Google Scholar
• Lagos R, Kotloff K, Hoffenbach A, Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants. Pediatr Infect Dis J 1998;17(4):294-304
   PubMed Web of Science ®Google Scholar
• Trotter CL, Ramsay ME, Slack MP. Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Public health 2003;6(1):55-8
   PubMedGoogle Scholar
• Madhi SA, Cutland C, Jones S, Immunogenicity and safety of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim) and monovalent hepatitis B vaccine at 6, 10 and 14 weeks of age in infants in South Africa. S Afr Med J 2011;101(2):126-13
   PubMed Web of Science ®Google Scholar
• Steiner M, Ramakrishnan G, Gartner B, Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life. BMC Infect Dis 2010;10:9
   PubMed Web of Science ®Google Scholar
• Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006;24(5):572-7
   PubMed Web of Science ®Google Scholar